EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma

Yumeng Pei, Meng Fang, Fan Zhang, Danyang Zhao, Yini Li, Jinyan Huang, Xingmei Liang, Rui-Ping Xiao, Tingbo Liang, Hong-Kun Wu

Cell Reports · 2026-10 · 45 (10) · 118000

DOI: 10.1016/j.celrep.2026.118000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-10. Verfasst von Yumeng Pei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Zh…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Interferon Regulatory Factor-7, Macrophages, Pancreatic Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In pancreatic ductal adenocarcinoma (PDAC), the desmoplastic stroma and immunosuppressive tumor microenvironment (TME) present barriers to immunotherapy. Here, we show that MG53 (TRIM72) is a critical regulator of macrophage fate and anti-tumor immunity; its myeloid-specific depletion accelerates PDAC progression by locking macrophages into a suppressive state, whereas its restoration dismantles the immunosuppressive TME. Mechanistically, MG53 binds the Irf7 locus to suppress the pro-tumorigenic myeloid program, and concomitant IRF7 deletion reverses the phenotype of MG53-deficient models. Clinically, an MG53-low/IRF7-high TAM signature correlates with reduced survival across gastrointestinal malignancies, particularly within PDAC cohorts. Using a macrophage-tropic mRNA-LNP platform to restore MG53 expression in vivo, thereby suppressing tumor growth and enhancing antitumor immune activity in PDAC. Our findings demonstrate that MG53 functions as a myeloid checkpoint regulator and suggest mRNA-based reprogramming as a potential strategy to address therapeutic resistance in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalInterferon Regulatory Factor-7MacrophagesPancreatic NeoplasmsAnimalsHumansMiceTumor MicroenvironmentCell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

CP: cancerCP: immunologyIRF7MG53mRNA immunotherapymacrophage polarizationtumor-associated macrophage

Substanzen

Interferon Regulatory Factor-7IRF7 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affi…
  • State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing 100871, China; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China.

Förderung

  • Zhejiang Province Natural Science Foundation
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Pei, Y., Fang, M., Zhang, F., Zhao, D., Li, Y., Huang, J., Liang, X., Xiao, R. P., Liang, T., & Wu, H. K. (2026). MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma. Cell Reports, 45(10), 118000. https://doi.org/10.1016/j.celrep.2026.118000

Vancouver

Pei Y, Fang M, Zhang F, Zhao D, Li Y, Huang J, et al. MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma. Cell Reports. 2026;45(10):118000. doi:10.1016/j.celrep.2026.118000

BibTeX
@article{Pei2026,
  author = {Pei, Yumeng and Fang, Meng and Zhang, Fan and Zhao, Danyang and Li, Yini and Huang, Jinyan and Liang, Xingmei and Xiao, Rui-Ping and Liang, Tingbo and Wu, Hong-Kun},
  title = {MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {10},
  pages = {118000},
  doi = {10.1016/j.celrep.2026.118000}
}
Kostenlos starten →